Literature DB >> 33394756

CORR Insights®: Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.

Xiaodong Tang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33394756      PMCID： PMC8083937          DOI： 10.1097/CORR.0000000000001625

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.755


× No keyword cloud information.
  11 in total

Review 1.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response.

Authors:  Jessica Menis; Baktiar Hasan; Benjamin Besse
Journal:  Eur Respir Rev       Date:  2014-09

Review 3.  Crizotinib.

Authors:  David F Heigener; Martin Reck
Journal:  Recent Results Cancer Res       Date:  2018

4.  Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.

Authors:  Chao Liu; Qi Jia; Haifeng Wei; Xinghai Yang; Tielong Liu; Jian Zhao; Yan Ling; Chenguang Wang; Hongyu Yu; Zhenxi Li; Jian Jiao; Zhipeng Wu; Cheng Yang; Jianru Xiao
Journal:  Lancet Oncol       Date:  2020-09       Impact factor: 41.316

5.  KinMutBase: a registry of disease-causing mutations in protein kinase domains.

Authors:  Csaba Ortutay; Jouni Väliaho; Kaj Stenberg; Mauno Vihinen
Journal:  Hum Mutat       Date:  2005-05       Impact factor: 4.878

Review 6.  Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.

Authors:  Tessa A Morris; Christine Khoo; Benjamin J Solomon
Journal:  Drugs       Date:  2019-08       Impact factor: 9.546

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 8.  Leiomyosarcoma.

Authors:  César Serrano; Suzanne George
Journal:  Hematol Oncol Clin North Am       Date:  2013-08-26       Impact factor: 3.722

9.  Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.

Authors:  Yoshiyuki Suehara; Shinji Kohsaka; Takuo Hayashi; Keisuke Akaike; Aiko Kurisaki-Arakawa; Shingo Sato; Eisuke Kobayashi; Sho Mizuno; Toshihide Ueno; Takeshi Morii; Tomotake Okuma; Taisei Kurihara; Nobuhiko Hasegawa; Kei Sano; Keita Sasa; Taketo Okubo; Youngji Kim; Hiroyuki Mano; Tsuyoshi Saito
Journal:  Clin Orthop Relat Res       Date:  2021-04-01       Impact factor: 4.755

10.  Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.

Authors:  Wendan Xu; Ji-Won Kim; Woo June Jung; Youngil Koh; Sung-Soo Yoon
Journal:  Cancer Res Treat       Date:  2017-06-19       Impact factor: 4.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.